Hitting 52 Week High, DexCom, Inc. (Nasdaq:DXCM) Settle At $152.73

0
11
DXCM
DXCM

DexCom, Inc. (Nasdaq:DXCM)

February 12th, 2019
With markets going up DexCom, Inc. closed Tuesday up 0.99%, a $1.50 increase to close on $152.73. Furthermore it hit a new 52 week high of $155.85. The stock continues to trade well at 186.55% of its 52 week low of $53.30. It’s expected that DexCom, Inc. will report earnings within the next couple of weeks.

Results from 16 analysts suggest that DexCom, Inc. might go down somewhat (-2.48%), while Finbox has calculated (with high uncertainty) a fair value price of $112.79.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Materials saw the biggest increase of the day (2.25%), while Real Estate saw the biggest drop (-0.70%). Industrials has seen the biggest year-to-date gain at 13.91%.

Materials saw the biggest turnaround from its 5-day performance of -1.14%, as it went up 2.25%. Real Estate saw a turn around from its 5-day performance of 0.96% trading down -0.70%.

Sector Breakdown

  • Materials went up with a 2.25% change.
  • Consumer Discretionary went up with a 1.66% change.
  • Industrials went up with a 1.56% change.
  • Financials went up with a 1.56% change.
  • Information Technology went up with a 1.36% change.
  • Healthcare went up with a 1.34% change.
  • Energy went up with a 1.18% change.
  • Communication Services went up with a 1.14% change.
  • Consumer Staples went up with a 0.88% change.
  • Utilities went up with a 0.17% change.
  • Real Estate went down with a -0.70% change.

DexCom, Inc. Info

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

All amounts in USD unless otherwise indicated
DXCM daily update

DXCM daily update



Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.